EIGR Profile
Eiger BioPharmaceuticals Inc. (EIGR) is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing drugs for the treatment of rare and ultra-rare diseases. The company's lead product candidate is Lonafarnib, which is being developed for the treatment of hepatitis delta virus (HDV) infection.
HDV is a life-threatening liver disease that affects millions of people worldwide. Lonafarnib is a first-in-class oral farnesyltransferase inhibitor that targets the prenylation step of HDV replication. The drug has received both orphan drug and breakthrough therapy designations from the FDA, and Eiger is conducting clinical trials to evaluate its safety and efficacy.
Eiger is also developing other product candidates, including Avexitide, which is being developed for the treatment of post-bariatric hypoglycemia, and Peginterferon Lambda, which is being developed for the treatment of hepatitis delta virus and COVID-19. Additionally, the company has a number of preclinical programs focused on the treatment of rare and ultra-rare diseases.
Founded in 2008 and headquartered in Palo Alto, California, Eiger is dedicated to developing innovative therapies for patients with unmet medical needs.
|
